NEW YORK — Preconception genetic testing startup Orchid said on Wednesday that it has raised $4.5 million in seed funding that it will use to help launch its saliva-based disease risk test.
The financing included investments from Refactor Capital, Village Global, Day One Ventures, Olive Capital, and Boom Capital, as well as the founders of 23andMe, Counsyl, Clover Health, Coinbase, Eventbrite, Flatiron, Oscar Health Insurance, and Stellar.